NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP
Lemaitre Vascular, Inc. LMAT
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY14 YEARS OF DIVIDEND GROWTH
Revenue · FY2025
$249.6M
▲ 13.5% vs FY2024
Dividend streak
14 yrs
Raised every year since 2012
EPS · FY25
$2.52
Dividend / sh · FY25
$0.80
Payout · FY25
31%
ROE · FY25
15.8%
Net margin · FY25
23.1%
Dividend coverage
3.1×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 249.6M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
23 cents of every revenue dollar became profit this year.
Per share
USD 2.52
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 3.1 times — the rest stayed in the company.
Profitability
15.8%
Return on equity, FY2025
ROE
Operating margin27.2%
Net margin23.1%
Return on assets9.9%
Each USD of equity produced 16 cents of profit this year.
Returned to shareholders
USD 18.1M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 18.1M
Net buybacksUSD -5.0M
Share of profit31.4%
Consecutive raises14 years
USD 18.1M in dividends — 31% of the year's profit went back to shareholders.
Growth
+14.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+15.6%
+14.0%
+12.3%
+10.5%
Net income
+40.9%
+22.2%
+22.2%
+16.3%
EPS, diluted
+39.4%
+19.4%
+19.6%
+13.6%
Dividend / share
+17.0%
+16.1%
+17.5%
Returned to shareholders
+18.1%
+18.7%
+20.3%
+14.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 615.7M
total assets, end of FY2025
Total assetsUSD 615.7M
EquityUSD 393.5M
CashUSD 28.2M
Current ratio12.89×
Equity funds 64% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.2
0.2
0.2
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
Operating income $B
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EBITDA $B
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
Net income $B
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
2.52
1.93
1.34
0.93
1.25
1.04
0.88
1.13
0.86
0.55
0.42
0.23
0.20
0.16
0.13
0.37
0.10
Dividend / sh $
0.80
0.64
0.56
0.50
0.44
0.38
0.34
0.28
0.22
0.18
0.16
0.14
0.12
0.10
0.08
·
·
Payout %
31
33
41
53
35
36
38
24
24
31
37
59
57
59
58
·
·
ROE %
15.8
13.9
10.6
7.9
12.6
13.2
12.9
19.1
17.4
12.8
10.6
6.3
5.9
4.9
4.1
12.0
3.3
Shares out B
0.02
0.02
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
66 of 66
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed